

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/010,317	01/21/1998	MAGNUS HOOK	TAMK:189	8522
75	90 03/26/2003			
M. SUZY STRICKLAND			EXAMINER	
ARNOLD WHITE & DURKEE P.O. BOX 4433			ZEMAN, ROBERT A	
HOUSTON, TX 772104433				
,	- ///		ART UNIT	PAPER NUMBER
			1645	ah
			DATE MAILED: 03/26/2003	54

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)			
Advisory Action	09/010,317	HOOK ET AL.			
	Examiner	Art Unit			
	Robert A. Zeman	1645			
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	lress		
THE REPLY FILED 27 February 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.					
PERIOD FOR RE	<u>[PLY</u> [check either a) or b)]				
a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Offictimely filed, may reduce any earned patent term adjustment. See 37 C	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF The date on which the petition under 37 CF of extension and the corresponding amount the shortened statutory period for reply the later than three months after the mail	g date of the final rejecting FINAL REJECTION. R 1.136(a) and the approperture of the fee. The appropriginally set in the final	on. See MPEP opriate extension ropriate extension Office action; or		
1. A Notice of Appeal was filed on 10 February 2003. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.					
2. The proposed amendment(s) will not be entered be	ecause:				
(a) they raise new issues that would require further	er consideration and/or search (s	see NOTE below);			
(b) they raise the issue of new matter (see Note b	elow);				
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or					
(d) they present additional claims without canceli	ng a corresponding number of fi	nally rejected claim	ıs.		
NOTE:					
$3. \boxtimes$ Applicant's reply has overcome the following rejecti	on(s): <u>see attached</u> .				
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed	amendment		
5.⊠ The a) affidavit, b) exhibit, or c) request for application in condition for allowance because: see		dered but does NO	T place the		
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which wer	e newly		
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we			and an		
The status of the claim(s) is (or will be) as follows:					
Claim(s) allowed: none.					
Claim(s) objected to: <u>none</u> .					
Claim(s) rejected: 54-59.					
Claim(s) withdrawn from consideration:					
8. The proposed drawing correction filed on is	a) approved or b) disapp	roved by the Exam	iner.		
9. Note the attached Information Disclosure Statemen	nt(s)(PTO-1449) Paper No(s)				
10. Other:					

1

Application/Control Number: 09/010,317

Art Unit: 1645

ADVISORY ACTION

The amendment filed on 2-27-2003 is acknowledged and has been entered. Claim 54 has been amended. Claims 54-59 are pending.

An appeal under 37 CFR 1.191 was filed in this application on 2-10-2003. Appellant's brief is due on 4-10-2003 in accordance with 37 CFR 1.192(a).

Applicant is reminded that newly submitted claim 54 is still directed to an invention that is independent or distinct from the invention originally claimed. As outlined in the previous Office action, SEQ ID NO:12, 14-16, 21-53, 62-85, 88-102 and 105 recited in claim 54 remain withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03. The examination of claim 54 remains limited to SEQ ID NO:2, 4, 6, 8, 10, 13, 17-20, 54-55, 57, 59-61, 86 and 103-104.

Priority

As outlined previously, the instant application is drawn to methods of generating an antibody that binds to a fibronectin-binding domain of a fibronectin-binding protein and inhibits the binding of said fibronectin-binding protein to fibronectin. Said method comprises administering to an animal or human a peptide of a fibronectin-binding protein that **does not** bind to fibronectin. Said peptides are recited as having the amino acid sequences of SEQ ID NO:2-4, 6, 8, 10, 13, 17-20, 54-55, 57, 59-61, 86 and 103-104. As stated previously, it is not apparent that all the claimed sequences are disclosed in the priority document 60/036,139. Applicant has provided a chart correlating the claimed SEQ ID NOs of the instant application with their support in application 60/036,1369. Unfortunately, said chart is insufficient with

Application/Control Number: 09/010,317

Art Unit: 1645

regard to SEQ ID NO:2 and 60-105. Said sequences need to be identified by page and line number when disclosed in a body of text (SEQ ID NO:60-62). Additionally, when said sequences are disclosed in a figure, it is suggested that a marked-up copy of said figure be used to identify said sequences. Consequently, with regard to SEQ ID NO:2 and 60-105, the filing date of the instant application will be used as the priority date.

Claim Rejections Withdrawn

The rejection of claim 54 under 35 U.S.C. 112, second paragraph, as being rendered vague and indefinite by the use of the term "consists essentially of" is withdrawn in light of the amendment thereto.

Claim Rejections Maintained

35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later

Application/Control Number: 09/010,317

Art Unit: 1645

invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The rejection of claims 54-59 rejected under 35 U.S.C. 103(a) as being unpatentable over Sun et al. (Infection and Immunity, Vol. 65, No. 2, 1997, pages 537-543 – IDS-5) is maintained for reasons of record. Applicant's assertion that the amendment to claim 54 was sufficient to overcome said rejection is incorrect. It was stated in the interview that said amendment would be sufficient to overcome the rejection under 35 U.S.C. 112, second paragraph (see Paper No 30).

The rejection of claims 54-59 rejected under 35 U.S.C. 103(a) as being unpatentable over Hook et al. (WO 92/02555 – IDS-5) is maintained for reasons of record. Applicant's assertion that the amendment to claim 54 was sufficient to overcome said rejection is incorrect. It was stated in the interview that said amendment would be sufficient to overcome the rejection under 35 U.S.C. 112, second paragraph (see Paper No 30).

The rejection of claims 54-59 rejected under 35 U.S.C. 103(a) as being unpatentable over Hook et al. (US Patent 5,440,014 – IDS-5) is maintained for reasons of record. Applicant's assertion that the amendment to claim 54 was sufficient to overcome said rejection is incorrect. It was stated in the interview that said amendment would be sufficient to overcome the rejection under 35 U.S.C. 112, second paragraph (see Paper No 30).

The rejection of claims 54-59 rejected under 35 U.S.C. 103(a) as being unpatentable over Huff et al. (Journal of Biological Chemistry Vol. 269, No. 22, 1994, pages 15563-155705 – IDS-

Application/Control Number: 09/010,317 Page 5

Art Unit: 1645

5) is maintained for reasons of record. Applicant's assertion that the amendment to claim 54 was

sufficient to overcome said rejection is incorrect. It was stated in the interview that said

amendment would be sufficient to overcome the rejection under 35 U.S.C. 112, second

paragraph (see Paper No 30).

Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Robert A. Zeman whose telephone number is (703) 308-7991.

The examiner can normally be reached on Monday- Thursday, 7am -5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Lynette Smith can be reached on (703) 308-3909. The fax phone numbers for the

organization where this application or proceeding is assigned are (703) 308-4242 for regular

communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is (703) 308-0196.

LYNETTE R. F. SMITH
SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600

Robert A. Zeman March 25, 2003